BIO-TECHNE TO PRESENT AT PHACILITATE ADVANCED THERAPIES WEEK 2025
Bio-Techne (NASDAQ: TECH) announced its participation at Phacilitate's Advanced Therapies Week, scheduled for January 20-23, 2025, in Dallas, Texas. The company will showcase its new ProPak™ GMP cytokines and cell and gene therapy solutions at booth 517.
Key highlights include the integration of ProPak liquid GMP cytokines with Wilson Wolf's G-Rex® bioreactor through ScaleReady, offering a closed process solution for T cell manufacturing. The company will also display the Ella™ automated ELISA platform and Simple Plex™ assays for QC release testing.
Dr. David Hermanson, Principal Scientist, will deliver a breakout session on closed system manufacturing on January 21 and host a product demonstration on January 22, focusing on ProPak cytokines integration in T cell manufacturing workflows. Will Geist, President of Bio-Techne's Protein Sciences Segment, emphasized the company's commitment to efficient manufacturing of cell and gene-modified cell therapies.
Bio-Techne (NASDAQ: TECH) ha annunciato la sua partecipazione alla Advanced Therapies Week di Phacilitate, prevista dal 20 al 23 gennaio 2025, a Dallas, Texas. L'azienda presenterà i suoi nuovi ProPak™ GMP cytokines e soluzioni per la terapia cellulare e genica presso lo stand 517.
Tra i punti salienti c'è l'integrazione dei cytokine liquidi GMP ProPak con il bioreattore G-Rex® di Wilson Wolf tramite ScaleReady, offrendo una soluzione di processo chiuso per la produzione di cellule T. L'azienda esporrà anche la piattaforma automatizzata ELISA Ella™ e gli assay Simple Plex™ per i test di rilascio QC.
Il Dr. David Hermanson, Scienziato Principale, terrà una sessione di approfondimento sulla produzione in sistemi chiusi il 21 gennaio e condurrà una dimostrazione del prodotto il 22 gennaio, concentrandosi sull'integrazione dei cytokine ProPak nei flussi di lavoro per la produzione di cellule T. Will Geist, Presidente del Segmento Scienze delle Proteine di Bio-Techne, ha sottolineato l'impegno dell'azienda per una produzione efficiente di terapie cellulari e genetiche modificate.
Bio-Techne (NASDAQ: TECH) anunció su participación en la Advanced Therapies Week de Phacilitate, programada del 20 al 23 de enero de 2025, en Dallas, Texas. La empresa presentará sus nuevos ProPak™ GMP cytokines y soluciones para terapia celular y génica en el stand 517.
Los aspectos destacados incluyen la integración de los citoquinas líquidos GMP ProPak con el bioreactor G-Rex® de Wilson Wolf a través de ScaleReady, ofreciendo una solución de proceso cerrado para la fabricación de células T. La compañía también exhibirá la plataforma automatizada ELISA Ella™ y los ensayos Simple Plex™ para pruebas de liberación de QC.
El Dr. David Hermanson, Científico Principal, ofrecerá una sesión especial sobre la fabricación en sistemas cerrados el 21 de enero y realizará una demostración de producto el 22 de enero, centrada en la integración de los citoquinas ProPak en los flujos de trabajo de fabricación de células T. Will Geist, Presidente del Segmento de Ciencias de las Proteínas de Bio-Techne, enfatizó el compromiso de la empresa con la fabricación eficiente de terapias celulares y génicamente modificadas.
Bio-Techne (NASDAQ: TECH)는 2025년 1월 20일부터 23일까지 텍사스 주 댈러스에서 열리는 Phacilitate의 Advanced Therapies Week에 참여한다고 발표했습니다. 이 회사는 부스 517에서 새로운 ProPak™ GMP 사이토카인 및 세포 및 유전자 치료 솔루션을 선보일 예정입니다.
주요 하이라이트로는 ScaleReady를 통한 Wilson Wolf의 G-Rex® 생물 반응기와 ProPak 액체 GMP 사이토카인의 통합이 있으며, 이를 통해 T 세포 제조를 위한 폐쇄형 프로세스 솔루션을 제공합니다. 회사는 또한 Ella™ 자동화 ELISA 플랫폼과 QC 방출 테스트를 위한 Simple Plex™ 분석을 전시할 것입니다.
수석 과학자인 David Hermanson 박사는 1월 21일에 폐쇄형 시스템 제조에 대한 세션을 진행하고, 1월 22일에는 T 세포 제조 작업 흐름에서 ProPak 사이토카인 통합에 초점을 맞춘 제품 데모를 개최할 예정입니다. Bio-Techne의 단백질 과학 부문 사장인 Will Geist는 세포 및 유전자 수정 세포 치료의 효율적인 제조를 위한 회사의 약속을 강조했습니다.
Bio-Techne (NASDAQ: TECH) a annoncé sa participation à la Advanced Therapies Week de Phacilitate, prévue du 20 au 23 janvier 2025 à Dallas, Texas. L'entreprise présentera ses nouvelles ProPak™ GMP cytokines et solutions pour la thérapie cellulaire et génique au stand 517.
Les points forts incluent l'intégration des cytokines liquides GMP ProPak avec le bioreacteur G-Rex® de Wilson Wolf via ScaleReady, offrant une solution de processus fermé pour la fabrication de cellules T. L'entreprise exposera également la plateforme ELISA automatisée Ella™ et les tests Simple Plex™ pour le contrôle qualité.
Le Dr. David Hermanson, Scientifique Principal, animera une session distincte sur la fabrication en systèmes fermés le 21 janvier et présentera une démonstration de produit le 22 janvier, axée sur l'intégration des cytokines ProPak dans les flux de travail de fabrication de cellules T. Will Geist, Président du Segment des Sciences des Protéines de Bio-Techne, a souligné l'engagement de l'entreprise envers une fabrication efficace des thérapies cellulaires et génétiquement modifiées.
Bio-Techne (NASDAQ: TECH) kündigte seine Teilnahme an der Advanced Therapies Week von Phacilitate an, die vom 20. bis 23. Januar 2025 in Dallas, Texas, stattfinden wird. Das Unternehmen wird seine neuen ProPak™ GMP-Zytokine und Lösungen für Zell- und Gentherapie am Stand 517 präsentieren.
Zu den wichtigsten Highlights gehört die Integration von ProPak flüssigen GMP-Zytokinen mit dem G-Rex® Bioreaktor von Wilson Wolf über ScaleReady, wodurch eine geschlossene Prozesslösung für die T-Zell-Herstellung geboten wird. Das Unternehmen wird auch die automatisierte ELISA-Plattform Ella™ und Simple Plex™ Assays für QC-Freigabetests ausstellen.
Dr. David Hermanson, Principal Scientist, wird am 21. Januar eine Breakout-Session zur Herstellung in geschlossenen Systemen halten und am 22. Januar eine Produktdemonstration durchführen, die sich auf die Integration von ProPak-Zytokinen in die T-Zell-Herstellungsabläufe konzentriert. Will Geist, Präsident des Proteinwissenschaftssegments von Bio-Techne, betonte das Engagement des Unternehmens für eine effiziente Herstellung von zell- und genmodifizierten Zelltherapien.
- None.
- None.
Bio-Techne will feature its cell and gene therapy workflow reproducibility and scalability solutions, including its portfolio of high-quality reagents and analytical technologies, at booth 517. Highlights include the recently launched ProPak liquid GMP cytokines, which combine with Wilson Wolf's G-Rex® bioreactor, available through ScaleReady, or similar platforms to enable a closed process solution to streamline and de-risk cytokine delivery for T cell manufacturing. The booth will also showcase the Ella™ automated ELISA platform and its Simple Plex™ assays, which represent the ideal solution for QC release testing, as well as Bio-Techne's full suite of protein analytical instruments for in-process and final product characterization of cell and gene therapies.
Dr. David Hermanson, Principal Scientist for Cell & Gene Therapy Research & Development at Bio-Techne, will present a breakout session on closed system manufacturing. The discussion will focus on strategies to ensure flexibility and scalability throughout all phases of cell therapy programs. He will also address critical regulatory, economic, and quality control factors to consider when selecting cell therapy manufacturing platforms. Dr. Hermanson's presentation will take place on Tuesday, January 21 at 12:15 PM.
Dr. Hermanson will also host a product demonstration in the Innovation Zone on Wednesday, January 22 at 10:00 AM, highlighting the integration of ProPak cytokines into T cell manufacturing workflows utilizing G-Rex bioreactors and the advantages of adopting closed system solutions. Both ProPak GMP cytokines and G-Rex bioreactors are available through Bio-Techne's strategic partnership with ScaleReady.
"Bio-Techne is deeply committed to the highly efficient manufacturing of lifesaving cell and gene-modified cell therapies," said Will Geist, President of Bio-Techne's Protein Sciences Segment. "ProPak GMP Cytokines provide the precise quantity of cytokines needed for highly simplified closed system expansion of CAR-T and TCR-T cell drug products with excellent cell characteristics. In addition to ProPaks, we are looking forward to showcasing our full suite of cell and gene therapy workflow solutions at this important conference."
Breakout Presentation:
Closed Systems, Open Possibilities: Considerations for Futureproofing Cell Therapy Manufacturing
Track: Cell Therapy Manufacturing
Session: Considering the End Early – What Parts of the Process Can You Get Right From the Start
Tuesday, January 21 at 12:15 PM, Theatre 1
Presenter: David Hermanson, Ph.D.
Innovation Zone Product Demonstration:
Streamlining Cytokine Delivery for Scalable, Closed System T Cell Manufacturing
Wednesday, January 22 at 10:00 AM, Innovation Zone
Presenter: David Hermanson, Ph.D.
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated approximately
About Bio-Techne Corporation (NASDAQ: TECH)
Contact: David Clair, Vice President, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416
About ScaleReady
ScaleReady provides the field of cell and gene-modified cell therapy (CGT) with a G-Rex centric manufacturing platform that enables the world's most practical, flexible, scalable, and affordable CGT drug product development and manufacturing.
The G-Rex manufacturing platform is currently used by a rapidly growing list of over 800 organizations and is producing drug products for approximately
CGT entities relying on the breadth and scope of ScaleReady's expertise can expect to save years of time and millions of dollars on the path to CGT commercialization.
For more information about the ScaleReady G-Rex® Grant Program, please contact info@scaleready.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-to-present-at-phacilitate-advanced-therapies-week-2025-302345274.html
SOURCE Bio-Techne Corporation
FAQ
What new products will Bio-Techne (TECH) showcase at Phacilitate Advanced Therapies Week 2025?
When and where is Bio-Techne (TECH) presenting at Phacilitate Advanced Therapies Week 2025?
What is the significance of Bio-Techne's (TECH) ProPak GMP cytokines for T cell manufacturing?
What will Dr. David Hermanson discuss in his presentations at the Phacilitate conference?
